<DOC>
	<DOCNO>NCT00047047</DOCNO>
	<brief_summary>This phase I trial study side effect , best way give , best dos tanespimycin without gemcitabine hydrochloride cisplatin treat patient advance solid tumor . Drugs use chemotherapy , tanespimycin , gemcitabine hydrochloride , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Using one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Tanespimycin , Gemcitabine Hydrochloride , Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) 17-AAG ( tanespimycin ) give day 1 8 every 3 week cycle combination Gemzar ( gemcitabine hydrochloride ) CDDP ( cisplatin ) ( cohorts A , B , E ) . II . To determine MTD 17-AAG plus Gemzar Gemzar give day 1 8 17-AAG give day 2 9 every 3 week ( cohort C ) . III . To determine MTD 17-AAG plus CDDP give day 1 8 every 3 week ( cohort D ) . IV . To define dose-limiting toxicity 17-AAG used combination Gemzar CDDP . V. To assess effect 17-AAG surrogate marker use combination Gemzar CDDP . VI . To report response observe . OUTLINE : This dose-escalation study . Patients assign 1 3 treatment cohort . Cohort A ( closed accrual 3/2/04 ) * : Patients receive escalate dos gemcitabine hydrochloride intravenously ( IV ) 30 minute , tanespimycin IV 1 hour , cisplatin IV 2 hour day 1 8 . NOTE : *The maximum tolerate dose ( MTD ) 3-drug combination determine 3/2/04 . Cohort B ( close accrual 3/2/05 ) : Patients receive gemcitabine hydrochloride** IV 30 minute , tanespimycin IV 1 hour , cisplatin** IV 2 hour day 1 8 . Cohort C : Patients receive gemcitabine hydrochloride** IV 30 minute tanespimycin IV 1-2 hour day 2 9 . Cohort D : Patients receive cisplatin** IV 2 hour tanespimycin IV 1-2 hour day 1 8 . Cohort E : Patients receive gemcitabine hydrochloride*** , tanespimycin*** , cisplatin*** cohort B . In cohort , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month . NOTE : **Gemcitabine hydrochloride cisplatin dosage constant , 17-AAG escalate cohort B , C , D. NOTE : ***Gemcitabine hydrochloride dosage constant , 17-AAG start high dose level cohort , cisplatin dosage escalate cohort E .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic proof cancer consider clinically unresectable Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelets ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; 2 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 2.5 x ULN Creatinine = &lt; 1.5 x ULN Alkaline phosphatase = &lt; 2 x ULN = &lt; 5 x ULN liver involvement Hemoglobin ( Hgb ) &gt; = 9.0 g/dL Ability provide inform consent Willingness return Mayo Clinic Rochester follow Life expectancy &gt; = 12 week Willingness provide biologic specimen require protocol ; mandatory translational research component Prior treatment gemcitabine cisplatin allow Patients prior anthracycline must normal ejection fraction multi gate acquisition scan ( MUGA ) Women childbearing potential : negative serum pregnancy test do = &lt; 7 day prior registration Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy ECOG performance status ( PS ) 2 , 3 4 Uncontrolled infection Any follow prior therapy : Chemotherapy = &lt; 4 week prior study entry Mitomycin C/nitrosoureas = &lt; 6 week prior study entry Immunotherapy = &lt; 4 week prior study entry Biologic therapy = &lt; 4 week prior study entry Radiation therapy = &lt; 4 week prior study entry , radiation potentially include heart field ( e.g. , mantle ) Radiation &gt; 25 % bone marrow Radiopharmaceuticals Chest radiation Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment Significant cardiac disease include : Heart failure meet New York Heart Association classification III IV History myocardial infarction = &lt; one year study entry Uncontrolled dysrhythmias require antiarrhythmic drug , Poorly control angina Active ischemic heart disease = &lt; 12 month prior study entry Congenital long QT syndrome Left bundle branch block Central nervous system ( CNS ) metastases seizure disorder Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , injection , intrauterine device [ IUD ] , abstinence , etc . ) Note : Concurrent use oral contraceptive contraindicate Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) History serious allergic reaction egg Concurrent use drug know inhibitor 3A4 enzyme &gt; = grade 2 peripheral neuropathy , define National Cancer Institute ( NCI ) Common Toxicity Criteria ( CTC ) version 2.0 Significant underlying pulmonary disease manifest requirement oxygen pulmonary fibrosis chest xray Use concomitant medication prolong may prolong correct QT interval ( QTc ) History serious ventricular arrhythmia ( ventricular tachycardia [ VT ] ventricular fibrillation [ VF ] , &gt; = 3 beat row ) , QTc &gt; = 450 msec men 470 msec woman , leave ventricular ejection fraction ( LVEF ) = &lt; 40 % MUGA Patients symptomatic pulmonary disease require medication include follow : dyspnea , dyspnea exertion , paroxysmal nocturnal dyspnea , oxygen requirement significant pulmonary disease , include chronic obstructive/restrictive pulmonary disease ; note : patient meet Medicare criterion home oxygen exclude protocol Patients prior history cardiac pulmonary toxicity receive anthracyclines doxorubicin , daunorubicin , mitoxantrone , bleomycin carmustine ( BCNU ) Patients great equal grade 2 pulmonary cardiac symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>